Last $146.49 USD
Change Today -0.78 / -0.53%
Volume 1.0M
As of 2:15 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2


Phone: 353 1 604 0031


mbursement when prescribed by a physician. The company offers approximately 100 ORx products that are reimbursable through many health plans and Medicaid and Medicare programs. ORx products offer consumers safe and effective remedies that provide an alternative to the higher out-of-pocket costs of traditional OTC products. The Rx Pharmaceuticals segment markets approximately 700 generic prescription and ORx products, with approximately 1,400 SKUs, to approximately 300 customers. Customers: The company’s U.S.-based customers are major wholesalers, including Cardinal Health, McKesson and AmerisourceBergen, as well as national and regional retail drug, supermarket and mass merchandise chains, including Walgreens, Walmart, CVS, Rite Aid, Kroger and Safeway. Competition: The company’s competitors include Actavis, Apotex, Glenmark Generics Inc., Impax, Prasco, Sandoz, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, and Zydus Pharmaceuticals. API The API segment develops, manufactures and markets active pharmaceutical ingredients (API) used worldwide by the generic drug industry and branded pharmaceutical companies. API development is focused on the synthesis of less common molecules for the U.S., European and other international markets. The company is also focusing development activities on the synthesis of molecules for use in its own OTC and Rx pipeline products. Research and Development The company's animal health products focus on both generic and branded product development. Its research and development spending was $115.2 million for fiscal 2013. Seasonality Revenues in the company’s Consumer Healthcare segment are subject to the seasonal demands for cough/cold/flu products in its second and third fiscal quarters and allergy products in its first and fourth fiscal quarters. The company’s sales of these products have varied from year to year based in large part on the severity and length of the cough/cold/flu season. Government Regulation The manufacturing, processing, formulation, packaging, labeling, testing, storing, distributing, advertising, and sale of the company’s products are subject to regulation by one or more U.S. agencies, including the FDA, the Federal Trade Commission, the U.S. Drug Enforcement Administration (DEA), the USDA, and the Consumer Product Safety Commission, as well as various foreign, state, and local agencies in localities in which the company’s products are sold. In addition, the company manufactures and markets certain of its products in accordance with standards set by organizations, such as the United States Pharmacopeial Convention, Inc. and NSF International (NSF). The company is subject to the requirements of the federal Controlled Substances Act and DEA regulations in the handling of any controlled substances in schedules II – V or any of the List I chemicals identified in the federal Controlled Substances Act. The company also has approximately 70 store brand products certified under NSF/American National Standards Institute Standard 173 for dietary supplement products. The company, through its affiliates located in the U.K., manufactures, packages, and distributes OTC pharmaceuticals, and provides contract manufacturing and packaging services for major pharmaceutical and healthcare companies in the U.K. and for export to markets outside the U.K. The manufacturing, processing, formulation, packaging, testing, labeling, advertising, and sale of these products are subject to regulation by one or more U.K. agencies, including the Medicines and Healthcare Products Regulatory Agency, the Department of Health, the Department of the Environment, Her Majesty’s Customs and Excise, the Department of Trade and Industry, the Health and Safety Executive, and the Department of Transport. The company manufactures, packages, and distributes Rx pharmaceutical, OTC pharmaceutical, and nutritional products in Mexico. The manufacturing, processing, formulation, packaging, labeling, testing, advertising, and sale of these products are subject to regulation by one or more Mexican agencies, including the Health Ministry, the Commercia


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $146.49 USD -0.78

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,701 INR +50.05
Endo International PLC $65.85 USD -0.45
Hospira Inc $50.86 USD -0.20
Mead Johnson Nutrition Co $92.35 USD -0.77
Mylan Inc/PA $50.29 USD -0.415
View Industry Companies

Industry Analysis


Industry Average

Valuation PRGO Industry Range
Price/Earnings 81.2x
Price/Sales 5.1x
Price/Book 2.3x
Price/Cash Flow 102.7x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at